Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...
Stephanie Desrosiers discusses strategies for oncology nurses to manage chemotherapy shortages, ensuring patient safety, ...
The FDA approved zidesamtinib for metastatic ROS1-positive NSCLC following prior kinase inhibitor therapy, offering hope for patients with resistance. The US Food and Drug Administration (FDA) has ...
NYU Langone experts discuss multidisciplinary care, diagnostic challenges, and nursing's role in treating rare bone and soft tissue sarcomas.
NYU Langone experts discuss multidisciplinary care, diagnostic challenges, and nursing's role in treating rare bone and soft tissue sarcomas.
NATCO Pharma receives tentative U.S. FDA approval for a generic version of the PARP inhibitor olaparib (Lynparza) for oncology indications. The U.S. Food and Drug Administration (FDA) has granted ...
Jeanelle S. King, PA-C, provides an in-depth look at nivolumab-relatlimab in a downloadable reference sheet. The efficacy of nivolumab plus relatlimab was evaluated in the phase 2/3 RELATIVITY-047 ...
The FDA has granted traditional approval to selpercatinib for adult and pediatric patients with RET fusion-positive solid tumors post-progression. The Food and Drug Administration (FDA) has converted ...
Linda Casey, RN, shares essential strategies for oncology nurses to protect vulnerable patients from the clinical risks of wildfire smoke exposure. As Canadian wildfire smoke blanketed the tri-state ...
The Food and Drug Administration (FDA) has approved gedatolisib (Revtorpyk) for use in combination with fulvestrant, with or without palbociclib. This approval specifically targets adult patients with ...
The WHO 2026 report warns of a global cancer surge by 2050, highlighting critical inequities and the need for people-centered oncology nursing care. The global oncology landscape is facing an ...
FDA Approves Sacituzumab Govitecan-hziy for First-Line Triple-Negative Breast Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results